[Federal Register Volume 71, Number 146 (Monday, July 31, 2006)]
[Notices]
[Page 43211]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-12172]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 28, 2005, MGI Pharma, 
6611 Tributary Street, Baltimore, Maryland 21224, made application to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Cocaine (9041), a basic class of controlled substance 
listed in Schedules II.
    The company plans to manufacture a cocaine derivative to be used in 
domestic and foreign clinical research studies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than September 29, 2006.

    Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-12172 Filed 7-28-06; 8:45 am]
BILLING CODE 4410-09-P